3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
173
Lymphoma, Non-Hodgkin
155
Leukemia, Lymphocytic, Chronic, B-Cell
154
Lymphoma, Large B-Cell, Diffuse
134
Lymphoma, Follicular
131
Lymphoma, Mantle-Cell
93
Leukemia
68
Lymphoma, B-Cell, Marginal Zone
67
Waldenstrom Macroglobulinemia
49
Burkitt Lymphoma
43
Lymphoma, B-Cell
40
Precursor Cell Lymphoblastic Leukemia-Lymphoma
36
Hodgkin Disease
36
Recurrence
24
Lymphoma, Large-Cell, Immunoblastic
24
Neoplasms
15
Myelodysplastic Syndromes
15
Lymphoma, Large-Cell, Anaplastic
15
Multiple Myeloma
13
Leukemia, Myeloid, Acute
12
Lymphoma, T-Cell, Cutaneous
9
Lymphoma, Extranodal NK-T-Cell
9
Leukemia, Hairy Cell
9
Intraocular Lymphoma
9
Hematologic Neoplasms
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Immunoblastic Lymphadenopathy
8
Sezary Syndrome
7
Mycosis Fungoides
7
Lymphoma, T-Cell
7
Interventions
Alpelisib
4
berzosertib
3
Fulvestrant
3
Everolimus
3
parsaclisib
2
Topotecan
2
NVP-BKM120
2
Cetuximab
2
talazoparib
1
sotorasib
1
serabelisib
1
ruxolitinib
1
duvelisib
1
dapagliflozin
1
cobimetinib
1
ceralasertib
1
binimetinib
1
avelumab
1
Vemurafenib
1
SF 1126
1
Rituximab
1
Paclitaxel
1
Oxaliplatin
1
Leuprolide
1
Leucovorin
1
Letrozole
1
Irinotecan
1
Goserelin
1
Fluorouracil
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hereditary Sensory and Autonomic Neuropathies
×
Rituximab
×
Clear all
NCT02204982
2023-09-28
DYNAMO + R
SecuraBio
Phase 3
Terminated
13 enrolled
10 charts
1 FDA